Integer Holdings Corporation
ITGR
$84.03
-5.06%
Integer Holdings Corporation is a leading manufacturer of critical medical device components, serving original equipment manufacturers (OEMs) across the healthcare industry, with its operations organized into three primary product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets. The company is a key outsourced manufacturing partner for major medical device firms, positioning itself as an essential, behind-the-scenes player in a stable and regulated industry. The current investor narrative is focused on the company's recent operational momentum, as evidenced by a stock surge following a Q4 earnings beat and subsequent analyst upgrades, which has sparked debate about whether this signals a sustainable recovery and growth trajectory within the medical device supply chain.…
ITGR
Integer Holdings Corporation
$84.03
Related headlines
Investment Opinion: Should I buy ITGR Today?
Rating: Hold. The core thesis is that Integer Holdings presents a high-risk, high-reward turnaround story where the potential valuation upside is compelling, but it is counterbalanced by significant profitability challenges and poor recent price momentum, warranting a cautious stance until earnings delivery is proven.
Supporting evidence includes a forward P/E of 12.16x that prices in a substantial earnings recovery, a strong 6-month price return of 30.14% indicating investor belief in the turnaround, a solid balance sheet with a debt-to-equity of 0.80 providing operational flexibility, and an estimated revenue base of $2.25 billion offering stability. However, these are offset by anemic current profitability (5.55% net margin), a stalled 1-month return of -2.79%, and a severe 1-year decline of -33.09% that underscores persistent fundamental issues.
The thesis would upgrade to a Buy if the company demonstrates consecutive quarters of earnings progress toward the $8.64 estimate, confirming the forward P/E is justified, and if the stock sustainably breaks above the $90 resistance level. It would downgrade to a Sell if quarterly EPS fails to show sequential improvement, if gross margins compress below 25%, or if the stock breaks below its recent consolidation support near $80. Based on the current data, the stock appears fairly valued for the risk, trading between deep value and a broken growth story.
Sign up to view all
ITGR 12-Month Price Forecast
The outlook for ITGR is bifurcated and highly dependent on the company's ability to deliver on implied earnings growth. The valuation is attractive only if the forward EPS estimate is credible, but current fundamentals do not support it. The stock is in a technical tug-of-war between a 6-month recovery and a 1-year downtrend. The stance is neutral due to this high uncertainty; the base case of range-bound trading is most probable as the story develops. The stance would upgrade to bullish on confirmation of margin expansion and sequential EPS growth. It would downgrade to bearish on a breakdown below $80 support or a significant earnings miss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Integer Holdings Corporation's 12-month outlook, with a consensus price target around $109.24 and implied upside of +30.0% versus the current price.
Average Target
$109.24
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$67 - $109
Analyst target range
Analyst coverage for Integer Holdings is extremely limited, with only two analysts providing estimates, which implies this is a smaller-cap stock with lower institutional interest, leading to potentially higher volatility and less efficient price discovery. The provided data includes revenue and EPS estimates but lacks a consensus price target, Buy/Hold/Sell distribution, and target price range; the estimated EPS average of $8.64 and revenue average of $2.25 billion provide a fundamental anchor, but without price targets, quantifying implied upside or downside and gauging the strength of analyst conviction is not possible.
Bulls vs Bears: ITGR Investment Factors
The investment debate for Integer Holdings centers on whether its recent operational momentum and attractive forward valuation signal a sustainable recovery, or if its weak profitability and stalled price action are signs of a dead-cat bounce within a longer-term downtrend. Currently, the bearish evidence holds stronger weight due to the stock's severe 1-year underperformance, anemic current earnings (EPS $0.04), and recent loss of upward momentum. However, the bullish case is supported by a compelling forward P/E of 12.16x and a strong 6-month rally of 30.14%. The single most important tension is the market's expectation of a dramatic earnings ramp to $8.64 per share. If Integer can deliver on these implied profitability gains, the stock is deeply undervalued. If earnings disappoint, the current price recovery will likely fail, and the stock could re-test its 52-week low.
Bullish
- Strong Recovery Momentum: The stock has posted a robust 30.14% return over the past six months, significantly outperforming the S&P 500's 5.66% gain. This surge, triggered by a Q4 earnings beat and analyst upgrades, suggests the market is pricing in a fundamental turnaround from the severe 1-year decline of -33.09%.
- Attractive Forward Valuation: The stock trades at a forward P/E of 12.16x, which is less than half its trailing P/E of 26.50x. This steep discount implies the market expects a significant earnings recovery, with the forward multiple appearing reasonable for a medical device manufacturer if the estimated EPS of $8.64 is achieved.
- Solid Financial Foundation: The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.80 and excellent liquidity, evidenced by a current ratio of 3.32. This financial stability provides a buffer against operational headwinds and supports investment in growth.
- High Short Interest as Potential Catalyst: A short ratio of 6.61 indicates significant bearish positioning. Any continuation of positive fundamental news, such as sustained earnings beats, could trigger a short squeeze, adding fuel to the ongoing recovery rally.
Bearish
- Severe Long-Term Downtrend: Despite the recent rebound, the stock remains down 33.09% over the past year and trades 34% below its 52-week high of $126.87. This deep correction reflects underlying fundamental challenges and a significant loss of investor confidence that may not be easily reversed.
- Weak Profitability Metrics: Current profitability is anemic, with a trailing EPS of just $0.0377 and a net margin of 5.55%. The gross margin of 26.99% is thin for a manufacturer, raising serious questions about the company's ability to expand earnings meaningfully from this depressed base.
- Stalled Near-Term Momentum: The 6-month rally has lost steam, with the stock down -2.79% and -3.26% over the past 1 and 3 months, respectively, underperforming the market by wide margins. This suggests consolidation and a lack of conviction to push the price beyond key resistance near $90.
- Limited Analyst Coverage & Visibility: With only two analysts providing estimates, there is minimal institutional research and price target guidance. This low coverage leads to less efficient price discovery and higher volatility, making it harder for investors to gauge fair value and consensus.
ITGR Technical Analysis
The stock is in a pronounced long-term downtrend, evidenced by a significant 1-year price decline of -33.09%, yet it is currently trading at approximately 66% of its 52-week range, positioned closer to the low of $62.00 than the high of $126.87, suggesting it may be in a value-seeking zone after a severe correction. Recent momentum shows a stark divergence, with a positive 6-month return of 30.14% indicating a strong recovery attempt, but this has stalled with negative 1-month and 3-month changes of -2.79% and -3.26%, respectively, signaling a potential consolidation or loss of upward momentum after the initial rebound. Key technical support is clearly defined at the 52-week low of $62.00, while resistance looms near the recent highs around $90; a sustained breakout above this resistance would be necessary to confirm a trend reversal, while the stock's high short ratio of 6.61 indicates significant bearish sentiment that could fuel volatility on any positive news.
Beta
0.71
0.71x market volatility
Max Drawdown
-50.1%
Largest decline past year
52-Week Range
$62-$126
Price range past year
Annual Return
-33.1%
Cumulative gain past year
| Period | ITGR Return | S&P 500 |
|---|---|---|
| 1m | -2.8% | +9.9% |
| 3m | -3.3% | +3.6% |
| 6m | +30.1% | +6.7% |
| 1y | -33.1% | +27.1% |
| ytd | +9.4% | +5.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ITGR Fundamental Analysis
Revenue trajectory analysis is constrained as specific quarterly revenue and growth rate figures are not available in the provided data; however, analyst estimates point to expected annual revenue of approximately $2.25 billion, suggesting the market is modeling a stable top-line performance. Profitability metrics show a company with thin margins, reporting a net margin of 5.55% and a gross margin of 26.99%, while a trailing EPS of $0.0377 indicates minimal profitability, raising questions about its ability to achieve meaningful earnings expansion from its current base. The balance sheet appears conservatively leveraged with a debt-to-equity ratio of 0.80, and strong liquidity is indicated by a current ratio of 3.32, but the return on equity of 5.89% is modest, suggesting the company is not generating high returns on shareholder capital despite its solid financial positioning.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ITGR Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The stock trades at a trailing P/E of 26.50x, which is significantly higher than its forward P/E of 12.16x; this wide gap implies the market expects a substantial near-term earnings acceleration, effectively pricing in robust future profitability growth. Compared to sector averages, data is not available for a direct industry P/E comparison; however, the forward P/E of 12.16x appears reasonable for a medical device manufacturer if growth expectations materialize, though the premium implied by the trailing multiple suggests current earnings are depressed. Historical context for the stock's own valuation range is unavailable, but the current price near 52-week lows suggests the market has already priced in significant pessimism, potentially setting the stage for multiple expansion if fundamental performance improves.
PE
26.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks stem primarily from weak profitability and execution risk. With a trailing EPS of $0.0377 and a gross margin of 26.99%, the company operates on thin margins. The core investment thesis hinges on a massive earnings expansion to an estimated $8.64 EPS. Any failure to achieve this projected profitability growth, whether from cost inflation, pricing pressure, or operational missteps, would severely undermine the forward valuation multiple of 12.16x and likely trigger a significant re-rating lower.
Market & Competitive Risks include valuation compression and sector-specific headwinds. The stock trades at a trailing P/E of 26.50x despite minimal current earnings, indicating it is priced for perfection. If growth expectations waver, this multiple could contract sharply. As a medical device component supplier, Integer is also exposed to concentration risk with its OEM customers and potential for those customers to insource production. The stock's high short ratio of 6.61 adds a layer of volatility risk, though it can also act as a catalyst.
Worst-Case Scenario involves a failure of the earnings recovery narrative, leading to multiple compression and a return to prior lows. A specific chain could be: Q3 earnings miss the high expectations, analysts withdraw upgrades, the forward P/E multiple contracts from 12x towards 8-10x, and bearish sentiment reasserts itself. This could realistically drive the stock back to its 52-week low of $62.00, representing a downside of approximately -26% from the current price of $84.03. The historical max drawdown of -50.11% shows the stock is capable of severe declines.
FAQ
The key risks are, in order of severity: 1) Execution Risk: The company must dramatically improve profitability from a net margin of 5.55% to justify its forward valuation; failure would cause a sharp decline. 2) Valuation Risk: The trailing P/E of 26.50x is high for current earnings, leaving the stock vulnerable to multiple compression. 3) Sentiment & Liquidity Risk: With only two analyst estimates and a high short ratio of 6.61, the stock is prone to high volatility and sentiment-driven swings. 4) Competitive Risk: As a contract manufacturer, Integer faces constant pricing pressure and the risk of customers insourcing production.
The 12-month forecast is highly uncertain, centered on three scenarios. The Base Case (50% probability) sees the stock trading between $80 and $95 as the company makes uneven progress. The Bull Case (30% probability) targets $100 to $115 if earnings meet the $8.64 estimate, triggering a re-rating and short squeeze. The Bear Case (20% probability) sees a drop to $62-$75 if the recovery narrative fails. The Base Case is most likely, implying the stock may struggle to make decisive gains in the near term without clearer fundamental improvement.
ITGR's valuation is a tale of two multiples, making it context-dependent. Based on trailing earnings (P/E of 26.50x), it appears overvalued given its weak profitability. However, based on forward expectations (P/E of 12.16x), it appears reasonably valued or even undervalued for a medical device manufacturer, assuming the estimated EPS of $8.64 is achieved. The market is currently paying a fair price for significant future growth that has not yet materialized. Therefore, the stock is neither clearly overvalued nor undervalued; it is fairly valued for the substantial execution risk it carries.
ITGR is a high-risk, speculative buy only suitable for investors with a strong tolerance for volatility. The potential reward is anchored by an attractive forward P/E of 12.16x, which prices in a massive earnings recovery to an estimated $8.64 EPS. However, the risk is high, given the company's current anemic profitability (EPS $0.04) and the stock's history of severe declines, including a 52-week low of $62. It could be a good buy for a contrarian investor who believes in the operational turnaround narrative and is prepared to withstand potential downside of 20-25% if the thesis fails.
ITGR is not suitable for short-term trading due to its volatility, low analyst coverage, and dependence on quarterly earnings catalysts that are high-risk events. It is better framed as a long-term (2-3 year) speculative investment for investors betting on a full operational turnaround. The thesis requires time for the company to execute its profitability improvement plan. Given the lack of a dividend and the stock's high beta characteristics (evidenced by a max drawdown of -50.11%), it should only be considered for the aggressive portion of a long-term portfolio.
